VYNE

+ Watchlist + Portfolio

VYNE Therapeutics Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.00
52-Week Range: $14.03 – $46.95
Market Cap: $19.07M
P/E (TTM): —
EPS (TTM): -27.58
Dividend Yield: —

Advanced Metrics

Price/Book: 0.77
PEG Ratio: —
Return on Equity: -63.16%
Return on Assets: -37.01%
Gross Margin: 100.00%
Operating Margin: -4437.21%
Profit Margin: 0.00%
Current Ratio: 20.86
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-20.40M
Revenue Growth: -57.40%
Earnings Growth: —
Enterprise Value: $-5.88M

VYNE Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$477.00K	$424.00K	$501.00K	$570.00K
Research & Development	$18.39M	$16.31M	$30.95M	$19.24M
Selling, General & Admin	$16.39M	$13.38M	$13.19M	$11.08M
Operating Expenses	$34.77M	$29.68M	$44.14M	$30.32M
Operating Income	-$34.30M	-$29.26M	-$43.64M	-$29.75M
EBITDA	-$34.22M	-$29.26M	-$43.63M	-$29.73M
Pretax Income	-$33.93M	-$27.87M	-$39.80M	-$26.73M
Income Tax	$13.00K	$0.00	$4.00K	$4.00K
Net Income	-$23.21M	-$28.45M	-$39.83M	-$26.48M
Diluted EPS	-7.28	-2.78	-0.93	-0.62
Diluted Shares	3.19M	10.27M	42.59M	42.77M

VYNE Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$30.91M	$30.62M	$19.93M	$24.03M
Receivables	$5.00M	$0.00	—	—
Current Assets	$38.27M	$95.96M	$64.44M	$30.01M
Total Assets	$40.76M	$97.69M	$66.91M	$30.16M
Current Liabilities	$9.35M	$7.54M	$14.82M	$2.40M
Total Debt	$0.00	$214.00K	$99.00K	$0.00
Total Liabilities	$9.56M	$8.95M	$14.82M	$2.40M
Retained Earnings	-$662.74M	-$691.34M	-$731.17M	-$757.65M
Shareholders' Equity	$31.20M	$88.73M	$52.09M	$27.77M
Working Capital	$28.93M	$88.42M	$49.62M	$27.61M

VYNE Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$29.20M	-$25.34M	-$33.97M	-$33.12M
Capital Expenditure	—	—	-$117.00K	—
Free Cash Flow	-$29.20M	-$25.34M	-$34.09M	-$33.12M
Depreciation & Amortisation	$72.00K	$0.00	$4.00K	$23.00K
Stock-Based Compensation	$4.30M	$3.31M	$3.30M	$2.31M
Investing Cash Flow	$15.67M	-$57.35M	$23.36M	$37.37M
Financing Cash Flow	$1.65M	$82.39M	-$141.00K	-$143.00K
Share Repurchases	—	-$360.00K	$0.00	—
Net Change in Cash	-$11.88M	-$301.00K	-$10.75M	$4.10M

VYNE Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$202.00K	$69.00K	$169.00K	$130.00K	$86.00K
Research & Development	$6.12M	$4.88M	$5.26M	$2.98M	$817.00K
Selling, General & Admin	$3.27M	$2.73M	$2.71M	$2.37M	$3.08M
Operating Expenses	$9.40M	$7.61M	$7.96M	$5.35M	$3.90M
Operating Income	-$9.20M	-$7.54M	-$7.79M	-$5.22M	-$3.82M
EBITDA	-$9.19M	-$7.54M	-$7.79M	-$5.21M	-$3.81M
Pretax Income	-$8.60M	-$5.75M	-$7.43M	-$4.96M	-$3.58M
Income Tax	$0.00	$0.00	$0.00	$4.00K	$0.00
Net Income	-$8.61M	-$5.75M	-$7.28M	-$4.84M	-$3.58M
Diluted EPS	-0.20	-0.13	-0.17	—	-0.08
Diluted Shares	42.67M	42.76M	42.80M	—	42.77M

VYNE Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$28.21M	$22.05M	$19.35M	$24.03M	$24.63M
Current Assets	$54.91M	$44.34M	$35.89M	$30.01M	$25.79M
Total Assets	$56.42M	$44.72M	$36.13M	$30.16M	$25.87M
Current Liabilities	$12.29M	$5.84M	$4.04M	$2.40M	$1.24M
Total Debt	$63.00K	$25.00K	$0.00	$0.00	—
Total Liabilities	$12.29M	$5.84M	$4.04M	$2.40M	$1.24M
Retained Earnings	-$739.78M	-$745.54M	-$752.82M	-$757.65M	-$761.24M
Shareholders' Equity	$44.13M	$38.88M	$32.09M	$27.77M	$24.64M
Working Capital	$42.62M	$38.51M	$31.84M	$27.61M	$24.55M

VYNE Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$11.46M	-$10.80M	-$7.10M	-$3.76M	-$4.08M
Free Cash Flow	-$11.46M	-$10.80M	-$7.10M	-$3.76M	-$4.08M
Depreciation & Amortisation	$6.00K	$6.00K	$6.00K	$5.00K	$6.00K
Stock-Based Compensation	$763.00K	$529.00K	$487.00K	$529.00K	$474.00K
Investing Cash Flow	$19.83M	$4.67M	$4.40M	$8.46M	$4.70M
Financing Cash Flow	-$87.00K	-$34.00K	-$7.00K	-$15.00K	-$15.00K
Net Change in Cash	$8.28M	-$6.16M	-$2.70M	$4.68M	$604.00K

Market Snapshot

About

VYNE Therapeutics is a pharmaceutical company focused on developing and commercializing therapeutics for immuno-inflammatory conditions. The company is advancing a pipeline of novel product candidates targeting dermatology and other inflammatory diseases.